Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection

Case report and review of the literature

Mauro S. Torno, Mallory D. Witt, Akihiko Saitoh, Courtney V Fletcher

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Efavirenz, a nonnucleoside reverse transcriptase inhibitor, is a highly effective and widely prescribed antiretroviral agent. It is recommended as first-line treatment of human immunodeficiency virus (HIV) infection. The standard dose of efavirenz is 600 mg/day; however, adverse central nervous system effects limit its use. Few data citing use of efavirenz at lower doses have been published. We describe a 35-year-old man with HIV infection whose virologic suppression was maintained after 18 months of treatment with efavirenz 400 mg/day. Genetic testing for cytochrome P450 (CYP) 2B6 showed that the patient was a heterozygous variant; patients with this polymorphism tend to have higher plasma efavirenz concentrations and slower plasma efavirenz clearance (prolonged elimination half-lives). Therapeutic drug monitoring also supported the dose reduction in this patient. Even with the 400-mg dose, the patient's plasma trough concentrations exceeded the upper limit of the therapeutic range. However, as he remained completely asymptomatic with this dose, no further dose reduction was necessary. This case report provides evidence that reduced efavirenz doses may be effective in the treatment of HIV infection. In addition, this case demonstrates that pharmacogenetic and pharmacokinetic testing combined with therapeutic drug monitoring may be used to guide reduced-dose, efavirenz-based therapy.

Original languageEnglish (US)
Pages (from-to)782-787
Number of pages6
JournalPharmacotherapy
Volume28
Issue number6
DOIs
StatePublished - Jun 1 2008

Fingerprint

efavirenz
Virus Diseases
HIV
Drug Monitoring
Anti-Retroviral Agents
Therapeutics
Reverse Transcriptase Inhibitors
Genetic Testing

Keywords

  • CYP2B6 polymorphism
  • Cytochrome P450
  • Low-dose efavirenz
  • Reduced-dose efavirenz

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection : Case report and review of the literature. / Torno, Mauro S.; Witt, Mallory D.; Saitoh, Akihiko; Fletcher, Courtney V.

In: Pharmacotherapy, Vol. 28, No. 6, 01.06.2008, p. 782-787.

Research output: Contribution to journalArticle

@article{390c13393d2f493cbee0e9be6f77b652,
title = "Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: Case report and review of the literature",
abstract = "Efavirenz, a nonnucleoside reverse transcriptase inhibitor, is a highly effective and widely prescribed antiretroviral agent. It is recommended as first-line treatment of human immunodeficiency virus (HIV) infection. The standard dose of efavirenz is 600 mg/day; however, adverse central nervous system effects limit its use. Few data citing use of efavirenz at lower doses have been published. We describe a 35-year-old man with HIV infection whose virologic suppression was maintained after 18 months of treatment with efavirenz 400 mg/day. Genetic testing for cytochrome P450 (CYP) 2B6 showed that the patient was a heterozygous variant; patients with this polymorphism tend to have higher plasma efavirenz concentrations and slower plasma efavirenz clearance (prolonged elimination half-lives). Therapeutic drug monitoring also supported the dose reduction in this patient. Even with the 400-mg dose, the patient's plasma trough concentrations exceeded the upper limit of the therapeutic range. However, as he remained completely asymptomatic with this dose, no further dose reduction was necessary. This case report provides evidence that reduced efavirenz doses may be effective in the treatment of HIV infection. In addition, this case demonstrates that pharmacogenetic and pharmacokinetic testing combined with therapeutic drug monitoring may be used to guide reduced-dose, efavirenz-based therapy.",
keywords = "CYP2B6 polymorphism, Cytochrome P450, Low-dose efavirenz, Reduced-dose efavirenz",
author = "Torno, {Mauro S.} and Witt, {Mallory D.} and Akihiko Saitoh and Fletcher, {Courtney V}",
year = "2008",
month = "6",
day = "1",
doi = "10.1592/phco.28.6.782",
language = "English (US)",
volume = "28",
pages = "782--787",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection

T2 - Case report and review of the literature

AU - Torno, Mauro S.

AU - Witt, Mallory D.

AU - Saitoh, Akihiko

AU - Fletcher, Courtney V

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Efavirenz, a nonnucleoside reverse transcriptase inhibitor, is a highly effective and widely prescribed antiretroviral agent. It is recommended as first-line treatment of human immunodeficiency virus (HIV) infection. The standard dose of efavirenz is 600 mg/day; however, adverse central nervous system effects limit its use. Few data citing use of efavirenz at lower doses have been published. We describe a 35-year-old man with HIV infection whose virologic suppression was maintained after 18 months of treatment with efavirenz 400 mg/day. Genetic testing for cytochrome P450 (CYP) 2B6 showed that the patient was a heterozygous variant; patients with this polymorphism tend to have higher plasma efavirenz concentrations and slower plasma efavirenz clearance (prolonged elimination half-lives). Therapeutic drug monitoring also supported the dose reduction in this patient. Even with the 400-mg dose, the patient's plasma trough concentrations exceeded the upper limit of the therapeutic range. However, as he remained completely asymptomatic with this dose, no further dose reduction was necessary. This case report provides evidence that reduced efavirenz doses may be effective in the treatment of HIV infection. In addition, this case demonstrates that pharmacogenetic and pharmacokinetic testing combined with therapeutic drug monitoring may be used to guide reduced-dose, efavirenz-based therapy.

AB - Efavirenz, a nonnucleoside reverse transcriptase inhibitor, is a highly effective and widely prescribed antiretroviral agent. It is recommended as first-line treatment of human immunodeficiency virus (HIV) infection. The standard dose of efavirenz is 600 mg/day; however, adverse central nervous system effects limit its use. Few data citing use of efavirenz at lower doses have been published. We describe a 35-year-old man with HIV infection whose virologic suppression was maintained after 18 months of treatment with efavirenz 400 mg/day. Genetic testing for cytochrome P450 (CYP) 2B6 showed that the patient was a heterozygous variant; patients with this polymorphism tend to have higher plasma efavirenz concentrations and slower plasma efavirenz clearance (prolonged elimination half-lives). Therapeutic drug monitoring also supported the dose reduction in this patient. Even with the 400-mg dose, the patient's plasma trough concentrations exceeded the upper limit of the therapeutic range. However, as he remained completely asymptomatic with this dose, no further dose reduction was necessary. This case report provides evidence that reduced efavirenz doses may be effective in the treatment of HIV infection. In addition, this case demonstrates that pharmacogenetic and pharmacokinetic testing combined with therapeutic drug monitoring may be used to guide reduced-dose, efavirenz-based therapy.

KW - CYP2B6 polymorphism

KW - Cytochrome P450

KW - Low-dose efavirenz

KW - Reduced-dose efavirenz

UR - http://www.scopus.com/inward/record.url?scp=47149109976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47149109976&partnerID=8YFLogxK

U2 - 10.1592/phco.28.6.782

DO - 10.1592/phco.28.6.782

M3 - Article

VL - 28

SP - 782

EP - 787

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6

ER -